National Vision Holdings Supports MAGENTIQ EYE's Series A Funding for AI Gastroenterology Innovations

MAGENTIQ EYE LTD. Secures Series A Funding to Propel AI Innovations in Gastroenterology

MAGENTIQ EYE LTD., a trailblazer in artificial intelligence (AI)-powered gastroenterology decision-support software, has successfully wrapped up its Series A funding round, which is poised to significantly bolster its commercial footprint in the United States and Europe. The funding round, led by aMoon—Israel's largest HealthTech investment fund—aims to enhance the capabilities of its flagship product, MAGENTIQ-COLO™, an FDA- and CE-approved software that revolutionizes polyp detection during colonoscopies. By offering real-time insights and advanced AI-generated reports that estimate polyp size and type, MAGENTIQ-COLO™ addresses a critical need in gastroenterological diagnostics, improving adenoma detection rates and potentially transforming patient outcomes.

The participation of notable investors, including Norgine Ventures BV, Nina Capital, Namarel Ventures SL, Nova Capital, and private investors Sake Bosch and Roon Doornink, underscores the growing interest and demand for innovative health technology solutions. As part of this investment, Roy Wiesner from aMoon will join MAGENTIQ EYE's board, bringing a wealth of experience in HealthTech that could catalyze the company’s strategic vision. CEO Dror Zur expresses enthusiasm about this partnership, emphasizing its potential to meet the increasing demand for their advanced diagnostic tools, particularly in a market where precision and efficiency are paramount.

MAGENTIQ EYE is not resting on its laurels; the company is actively engaged in clinical trials targeting specialized diseases, including ulcerative colitis and early dysplasia in Barrett's esophagus. The funding will facilitate the development of these innovative diagnostic tools, thereby supporting the company’s goal of enhancing patient care through cutting-edge technology. Wiesner highlights MAGENTIQ's software as the most accurate on the market, noting its scalability and flexibility across various gastrointestinal applications. With a robust pipeline of studies and inquiries, this investment represents a significant leap towards the realization of MAGENTIQ EYE's ambition to transform the landscape of health technology and improve patient outcomes on a global scale.

In addition to its core offerings, MAGENTIQ EYE's commitment to innovation positions it as a leader in the burgeoning field of AI-assisted medical diagnostics. The company’s focus on addressing specific gastrointestinal conditions through targeted clinical trials not only strengthens its market position but also showcases its dedication to improving health outcomes. As the healthcare sector increasingly embraces AI technology, MAGENTIQ EYE is at the forefront, ready to make a lasting impact in gastroenterology.

With this infusion of capital and strategic direction, MAGENTIQ EYE is set to redefine the standards of care in the gastroenterology field, potentially changing the way practitioners diagnose and treat gastrointestinal diseases.